Everist Health, Inc. (EGI) focuses on developing and commercializing unique diagnostics, prognostics, and therapeutic selection technologies for cancer, cardiovascular disease, and metabolic disease. Their mission is to drive growth by creating innovative prognostics that have a significant impact on medical and financial outcomes. They achieve this through proprietary research and development, targeted acquisitions, and in-licensing. Everist Health utilizes their Evolver technology platform to accelerate the development of molecular prognostic tests. Their flagship product, the AngioDefender CVD diagnostic system, is the world's first non-invasive device that combines sensor technology and software algorithms to assess early-stage cardiovascular disease and atherosclerosis. Additionally, they have transformed their Vascular Age Calculator into the COVIDAge Risk Calculator to help individuals understand their risks for COVID-19 complications. Everist Health was established in 2012 to market the AngioDefender, a quick and CE-mark approved test that detects cardiovascular disease risk, empowering individuals to make positive changes to their health.